Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Titel:
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Auteur:
Prasath, Vishnu Boutrid, Hinda Wesolowski, Robert Abdel-Rasoul, Mahmoud Timmers, Cynthia Lustberg, Maryam Layman, Rachel M. Macrae, Erin Mrozek, Ewa Shapiro, Charles Glover, Kristyn Vater, Mark Budd, G. Thomas Harris, Lyndsay Isaacs, Claudine Dees, Claire Perou, Charles M. Johnson, Gary L. Poklepovic, Andrew Chen, Helen Villalona-Calero, Miguel Carson, William Stover, Daniel G. Ramaswamy, Bhuvaneswari